ArticleAntioxidants (Basel, Switzerland)2022
Quercetin Regulates Key Components of the Cellular Microenvironment during Early Hepatocarcinogenesis.
Article in Antioxidants (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 24 citations in OpenAlex.
- Identification and validation of a plasma metabolomics-based model for risk stratification of intrahepatic cholangiocarcinoma.Journal of cancer research and clinical oncology · 2023Trial
- Quercetin and low-dose gamma irradiation modulate oxidative stress, inflammation, autophagy, and apoptosis in DEN-induced hepatocarcinogenesis.Genes & nutrition · 2026Article
- Quercetin alleviates CClBiochemistry and biophysics reports · 2026Article
- Quercetin-loaded composite materials for bone regeneration: a review of carriers, controlled release, and mechanistic advances.Stem cell research & therapy · 2026Review
- Quercetin, Kaempferol and Capsaicin Counteract the TGF-β1-Induced Upregulation of αSMA and Collagen in Myoblasts.International journal of molecular sciences · 2025Article
- Polystyrene microplastics induce liver fibrosis and lipid deposition in mice through three hub genes revealed by the RNA-seq.Scientific reports · 2025Article
- Integrating Network Pharmacology and Experimental Validation to Decipher the Mechanism of Action ofDrug design, development and therapy · 2024Article
- Apoptotic Mechanisms of Quercetin in Liver Cancer: Recent Trends and Advancements.Pharmaceutics · 2023Review
- Plant-derived natural products and combination therapy in liver cancer.Frontiers in oncology · 2023Review
- Glycogen overload transforms the liver.Acta biochimica et biophysica Sinica · 2022Article
- Effects of Sorafenib and Quercetin Alone or in Combination in Treating Hepatocellular Carcinoma: In Vitro and In Vivo Approaches.Molecules (Basel, Switzerland) · 2022Article
- The potential mechanism of Longsheyangquan Decoction on the treatment of bladder cancer: Systemic network pharmacology and molecular docking.Frontiers in pharmacology · 2022Article
- Targeting of non-apoptotic cancer cell death mechanisms by quercetin: Implications in cancer therapy.Frontiers in pharmacology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 1 country.
Funding
Abstract
Hepatocellular carcinoma (HCC) is a health problem worldwide due to its high mortality rate, and the tumor microenvironment (TME) plays a key role in the HCC progression. The current ineffective therapies to fight the disease still warrant the development of preventive strategies. Quercetin has been shown to have different antitumor activities; however, its effect on TME components in preneoplastic lesions has not been fully investigated yet. Here, we aimed to evaluate the effect of quercetin (10 mg/kg) on TME components during the early stages of HCC progression induced in the rat. Histopathological and immunohistochemical analyses showed that quercetin decreases the size of preneoplastic lesions, glycogen and collagen accumulation, the expression of cancer stem cells and myofibroblasts markers, and that of the transporter ATP binding cassette subfamily C member 3 (ABCC3), a marker of HCC progression and multi-drug resistance. Our results strongly suggest that quercetin has the capability to reduce key components of TME, as well as the expression of ABCC3. Thus, quercetin can be an alternative treatment for inhibiting the growth of early HCC tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.